Department of Biomedical Sciences, Irvine3 Circulation/Vascular Labs & San Valentino Vascular Screening Project, G D'annunzio University, Chieti, Pescara, Italy.
Panminerva Med. 2010 Dec;52(4):269-75.
The aim of this study was to evaluate the efficacy of colostrum (ARD Colostrum) in association with the immunomodulator Bifivir in the prevention of flu episodes compared with anti-flu vaccination. The registry groups included no prevention, vaccination, vaccination+immunomodulators, and immunomodulators only. Groups were comparable for age and sex distribution. In the group without prevention there were 8 major episodes and 12 minor episodes out of 34 subjects (8-12/34); in the vaccination group the respective figures were 8-13/38; in the group treated with a combination of vaccination and immunomodulators (ARD Colostrum + Bifivir) the figures were 4-9/33; and in the group treated with immunomodulators only there were 11 viral episodes (3-8) in 36 subjects. The episodes in the vaccination+immunomodulators and immunomodulators only groups were significantly lower compared with the other two groups (P<0.05). The number of episodes registered with the immunnomodulators was significantly lower than those observed in patients using vaccination or no prevention (P<0.05). The number of days of disease was higher in untreated controls compared to the groups treated with immunomodulators (P<0.05) and 2 times higher in the vaccination group compared to the same groups (P<0.05). The average relative costs were significantly lower (2.3 times) in the immunomodulators groups in comparison with the other groups (P<0.05). No problems concerning tolerability or side effects were observed during the study. Compliance was very good. In conclusion, the administration of immunomodulators is very cost effective and appears to be more effective than vaccination to prevent flu.
本研究旨在评估初乳（ARD 初乳）与免疫调节剂 Bifivir 联合用于预防流感发作的疗效，与流感疫苗接种进行比较。登记组包括无预防、疫苗接种、疫苗接种+免疫调节剂和仅免疫调节剂。各组在年龄和性别分布方面具有可比性。在无预防组中，34 名受试者中有 8 次主要发作和 12 次次要发作（8-12/34）；疫苗接种组分别为 8-13/38；在联合使用疫苗接种和免疫调节剂（ARD 初乳+Bifivir）治疗的组中，数字为 4-9/33；而在仅使用免疫调节剂治疗的组中，36 名受试者中有 11 次病毒发作（3-8）。疫苗接种+免疫调节剂和仅免疫调节剂治疗组的发作次数明显低于其他两组（P<0.05）。免疫调节剂组的发作次数明显低于使用疫苗接种或无预防的患者（P<0.05）。未治疗对照组的疾病天数明显高于使用免疫调节剂治疗的组（P<0.05），且与相同组相比，疫苗接种组的疾病天数高 2 倍（P<0.05）。与其他组相比，免疫调节剂组的平均相对费用明显降低（2.3 倍）（P<0.05）。在研究期间未观察到与耐受性或副作用相关的问题。依从性非常好。总之，免疫调节剂的给药具有非常高的成本效益，并且似乎比疫苗接种更能有效预防流感。
